Latest Posts, Page 2

Lymphoma Canada,article about lymphoma cancer prognosis,lymphedema causes

FDA Approves Rituxan Hycela for Blood Cancers

Rituxan Hycela (rituximab) was granted approval by the Food and Drug Administration (FDA) for adult patients with previously untreated and r...

More focus is now being put on the needs of adolescents and young adults (AYA) with cancer. For example, a phase 2 trial is investigati...

According to updated findings from the core group of the phase 1 TRANSCEND study, treatment with JCAR017 showed a 59 percent complete respon...

Regardless of previous treatment with Adcetris (brentuximab vedotin), patients with relapsed or refractory Hodgkin lymphoma who had autologo...

There is currently no standard of care for patients with relapsed or refractory mantle cell lymphoma (MCL), but a recent phase 2 study prove...

Researchers are anticipating novel combinations to improve care in the treatment of mantle cell lymphoma (MCL) as the treatment paradigm con...

Axicabtagene ciloleucel (KTE-C19; axi-cel) was granted a priority review by the Food and Drug Administration (FDA) for the treatment of tran...

There is currently no uniform procedure for patients with double-hit lymphoma (DHL) that prolongs benefit. Some patients receive autologous ...

Copanlisib was granted a priority review designation by the Food and Drug Administratioin (FDA) for the treatment of patients with relapsed/...

There were nearly identical response rates and toxicity with subcutaneous administration of Rituxan (rituximab) and IV administration of the...